Carbamazepin Tillomed

  • Procedure started
  • Under evaluation
  • CHMP opinion
  • European Commission final decision
Current status
European Commission final decision

Overview

EMA recommends authorisation of Carbamazepin Tillomed (carbamazepine, 200 and 400 mg prolonged release tablets) in the EU

On 30 April 2020, the European Medicines Agency completed a review of Carbamazepin Tillomed and associated names following a disagreement among EU Member States regarding its authorisation. The Agency concluded that the benefits of Carbamazepin Tillomed outweigh its risks, and the marketing authorisation can be granted in Germany and the Member States of the EU where the company has applied for marketing authorisation (Croatia, Italy, Netherlands, Poland and Sweden), as well as in the United Kingdom.

Key facts

About this medicine
Approved name
Carbamazepin Tillomed
International non-proprietary name (INN) or common name
carbamazepin
Associated names
  • Carbamazepin Tillomed
  • Carbamazepina Tillomed
  • Karbamazepin Tillomed
  • Karbamazepina Tillomed
About this procedure
Current status
European Commission final decision
Reference number
EMEA/H/A-29(4)/1497
Type
Article 29(4) referrals

This type of referral is triggered when there is a disagreement between Member States regarding a marketing authorisation application being evaluated in a mutual-recognition or decentralised procedure, on the grounds of a potential serious risk to public health.

Authorisation model
Nationally authorised product(s)
Key dates and outcomes
CHMP opinion date
30/04/2020
EC decision date
25/06/2020

All documents

European Commission final decision

  • List item

    Carbamazepin Tillomed Article 29(4) referral - EMA recommends authorisation of Carbamazepin Tillomed (carbamazepine, 200 and 400 mg prolonged release tablets) in the EU (PDF/110.02 KB)


    First published: 30/04/2020
    Last updated: 21/07/2020
    EMA/388917/2020

  • List item

    Carbamazepin Tillomed Article 29(4) referral - Annex II (PDF/99.04 KB)


    First published: 21/07/2020

  • List item

    Carbamazepin Tillomed Article 29(4) referral - Annex I (PDF/72.56 KB)


    First published: 21/07/2020

  • List item

    Carbamazepin Tillomed Article 29(4) referral - Assessment report (PDF/215.51 KB)

    Adopted

    First published: 03/07/2020
    EMA/352448/2020

  • List item

    Carbamazepin Tillomed Article 29(4) referral - Annex III (PDF/64.76 KB)


    First published: 30/04/2020
    Last updated: 21/07/2020

  • Description of documents published

    Please note that some of the listed documents apply only to certain procedures.

    • Overview - lay-language summary of the stage of the procedure
    • Notification – a letter from a Member State, the European Commission or the marketing authorisation holder requesting the initiation of the procedure
    • Scientific background – further background information from the triggering Member State on the issues leading to the initiation of the procedure (if applicable)
    • List of questions – questions agreed by the Committee requesting further information from the marketing authorisation holder(s) / applicant(s) to evaluate the issues identified
    • Timetable for the procedure – agreed timeframe to respond to the list of questions, to assess the issues and to adopt a conclusion
    • List of medicines concerned by the procedure – medicine(s) / active substance(s) concerned, and marketing authorisation holder(s) / applicant(s)
    • List of questions to be addressed by the stakeholders – call for data to be submitted by stakeholders (e.g. healthcare professionals, patient organisations, individual patients) (if applicable)
    • Stakeholder submission form – form to be used by stakeholders to submit data (if applicable)
    • Scientific conclusions – scientific conclusions of the PRAC and/or CHMP and/or CMDh
    • Assessment report – PRAC or CHMP assessment and conclusions on the issues investigated, including divergent positions (if applicable)
    • Divergent positions – divergent positions of the CHMP or CMDh members for pharmacovigilance procedures (if applicable)
    • Changes to the summary of product characteristics, labelling and package leaflet (amended sections or fully revised version) (if applicable)
    • Condition(s) to the marketing authorisation(s) – condition(s) for the safe and effective use of the medicine(s) (if applicable)
    • Condition for lifting the suspension – condition to be fulfilled for the suspension of the marketing authorisation(s) to be lifted (if applicable)
    • Timetable for implementation of CMDh position – agreed timeframe to submit and finalise the variation(s) implementing the outcome of the procedure (if applicable)

    Note that older documents may have different titles.

    News

    How useful was this page?

    Add your rating
    Average
    1 rating